GARDNER PHYLLIS 4
4 · Revance Therapeutics, Inc. · Filed Mar 16, 2018
Insider Transaction Report
Form 4
GARDNER PHYLLIS
Director
Transactions
- Sale
Common Stock
2018-03-16$31.51/sh−5,333$168,045→ 3,000 total - Exercise/Conversion
Common Stock
2018-03-16+4,000→ 0 totalExercise: $2.55Exp: 2018-04-29→ Common Stock (4,000 underlying) - Exercise/Conversion
Common Stock
2018-03-16+1,333→ 0 totalExercise: $2.55Exp: 2020-07-20→ Common Stock (1,333 underlying) - Exercise/Conversion
Common Stock
2018-03-16$2.55/sh+1,333$3,399→ 8,333 total - Exercise/Conversion
Common Stock
2018-03-16$2.55/sh+4,000$10,200→ 7,000 total
Footnotes (3)
- [F1]The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.50 to $31.55. Dr. Gardner undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F2]The option is fully vested as of January 1, 2012.
- [F3]The Option is fully vested as of January 1, 2014.